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ABSTRACT
Introduction: As an increasing number of people are
living with more than 1 long-term condition, identifying
effective interventions for the management of
multimorbidity in primary care has become a matter of
urgency. Interventions are challenging to evaluate due
to intervention complexity and the need for adaptability
to different contexts. A process evaluation can provide
extra information necessary for interpreting trial results
and making decisions about whether the intervention is
likely to be successful in a wider context. The 3D
(dimensions of health, drugs and depression) study
will recruit 32 UK general practices to a cluster
randomised controlled trial to evaluate effectiveness of
a patient-centred intervention. Practices will be
randomised to intervention or usual care.
Methods and analysis: The aim of the process
evaluation is to understand how and why the
intervention was effective or ineffective and the effect
of context. As part of the intervention, quantitative
data will be collected to provide implementation
feedback to all intervention practices and will
contribute to evaluation of implementation fidelity,
alongside case study data. Data will be collected at
the beginning and end of the trial to characterise each
practice and how it provides care to patients with
multimorbidity. Mixed methods will be used to collect
qualitative data from 4 case study practices,
purposively sampled from among intervention
practices. Qualitative data will be analysed using
techniques of constant comparison to develop codes
integrated within a flexible framework of themes.
Quantitative and qualitative data will be integrated to
describe case study sites and develop possible
explanations for implementation variation. Analysis
will take place prior to knowing trial outcomes.
Ethics and dissemination: Study approved by
South West (Frenchay) National Health Service (NHS)
Research Ethics Committee (14/SW/0011). Findings
will be disseminated via a final report, peer-reviewed
publications and practical guidance to healthcare
professionals, commissioners and policymakers.
Trial registration number: ISRCTN06180958.
INTRODUCTION
Multimorbidity presents considerable chal-
lenges for the organisation and delivery of
healthcare because of the increased com-
plexity of managing several coexisting condi-
tions and the increased demand on time and
resources.1 2 It is now a common situation in
primary care1 and the need to find efficient
and effective approaches to this challenge is
becoming more urgent as multimorbidity
becomes more prevalent.3 However, there is
a current lack of evidence about which inter-
ventions may be effective.4 Successful
Strengths and limitations of this study
▪ A context-sensitive, preplanned process evalu-
ation of a highly complex health service interven-
tion addressing an important healthcare
challenge.
▪ The main limitation is the number of case
studies and that a usual care case study is not
included. However, we have planned a compre-
hensive survey of practice characteristics and
usual care in all practices at the beginning and
end of the trial to evaluate the influence of
context.
▪ A strength of this evaluation is that it has been
subject to careful prioritisation based on a
detailed description of the intervention and of
the trial processes (figures 1 and 2).
▪ Key decisions about focus have been made pro-
spectively, but by committing to only four case
studies initially, we have retained flexibility to
respond to emerging issues and/or to investigate
one usual care practice.
▪ Depth of evaluation in the case studies has been
balanced with breadth by collection of quantita-
tive implementation data from all intervention
practices to contribute to assessment of fidelity
of adoption, delivery and maintenance.
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interventions are likely to be complex and pragmatic in
order to be transferable to different patient situations
and different healthcare contexts and will need to be
tested in large-scale multisite trials. Evaluation is there-
fore challenging. This paper presents the protocol for
the process evaluation of a trial of one such
intervention.
The 3D study
The trial that is the subject of this process evaluation is a
multisite cluster randomised controlled trial of an inter-
vention to improve the management of people with mul-
timorbidity in general practice—the 3D (dimensions of
health, drugs and depression) study. The 3D study
protocol is published in full,5 so this paper will only
briefly describe the 3D intervention to give context to
the process evaluation design.
The 3D intervention is driven by the concept of patient-
centred care, developed from previously published defi-
nitions6 7 and stated in the trial protocol as:
▸ A focus on the patient’s individual disease and illness
experience: exploring the main reasons for their visit,
their concerns and need for information.
▸ A biopsychosocial perspective: seeking an integrated
understanding of the whole person, including their
emotional needs and life issues.
▸ Finding common ground on what the problem is and
mutually agreeing management plans.
▸ Enhancing the continuing relationship between the
patient and doctor (the therapeutic alliance).
The intervention aims to address known problems for
people with multimorbidity. These include high illness
burden, high treatment burden, poorly coordinated
care, low quality of life, increased risk of depression and
polypharmacy.8–10 The intervention consists of strategies
to address these problems (figure 1) implemented at
general practice level and individual clinician level,
which include improved continuity, coordination and
integration of care combined with a more holistic
approach to achieve patient-centred delivery of care.
Each patient will be allocated a specific general practi-
tioner (GP), and nurse if appropriate, who will review all
of the patient’s long-term conditions (LTCs) in a single,
longer, holistic, two-part review (3D review), repeated six
monthly. The review is intended to balance the patient’s
agenda and quality of life issues with disease control and
will replace separate disease-focused reviews. Each review
addresses the 3Ds of dimensions of health, drugs and
depression.
General practices (GP practices) in two areas of
England and in one part of Scotland will be recruited.
The research team will train those randomised to deliver
the intervention, and will discuss with them how they
will fit the intervention to their own context in a way
that maintains fidelity of function.11 The clinical staff
(GPs and nurses) will be trained to implement certain
strategies that fall within a patient-centred approach
when reviewing those patients and to use a new
consultation template that automatically adapts to the
individual’s conditions and supports the intervention.
Reception staff in the GP practices will receive training
to arrange the reviews and other appointments of the
identified patients with their usual nurse or GP in
extended time slots.
An external pilot took place prior to the main trial
and influenced the final trial design. It was subject to a
formative process evaluation, the aim of which was to
support optimisation of the intervention by identifying
processes that could be improved and factors that might
threaten implementation of the intervention. It also pro-
vided the opportunity to test the process evaluation
design for the main trial. Findings from this stage that
resulted in changes to the intervention design are
reported in the linked paper by Man et al.5
Process evaluation
A process evaluation accompanying a randomised con-
trolled trial aids evaluation of the effectiveness of an
intervention by investigating how it was implemented,
the mechanisms by which it achieved its effect and how
the intervention interacted with the context in which it
was implemented.12–15 Researchers conducting process
evaluations typically investigate the extent to which the
intervention is reaching the participants for whom it is
intended (reach), whether all the intervention compo-
nents are being delivered as intended by the research
team (delivery and fidelity), participants’ experiences of
receiving an intervention (response), the extent to
which an intervention is maintained over time (mainten-
ance), and contextual factors that may influence main-
tenance and the precise form of the intervention
delivered.12 16–18 Process evaluations can help research-
ers to distinguish between intervention failure (where
the intervention concept is flawed), and implementation
failure (where the intervention is poorly delivered).13 19
Theory may be used to focus the evaluation and provide
additional insight into causal mechanisms affecting
outcomes.14 20 21
Arguably, process evaluations are particularly necessary
in multisite, pragmatic trials, where there is likely to be
variation in the way the ‘same’ intervention is implemen-
ted.13 In cluster trials, outcomes are often measured at
the individual level but the intervention is applied by
the research team to the cluster, which implements it
and applies it at the individual level. There may there-
fore be processes operating at both cluster and individ-
ual level, which are candidates for evaluation.22
Evaluation of processes within control clusters may also
be important, for example, to understand the ‘usual
care’ comparator.22
Process evaluations may employ mixed methods, both
quantitative and qualitative, and apply these at different
stages of the trial depending on the purpose of the
evaluation.16–18 21 They may be used to optimise the
design of the intervention and/or to provide insight
into outcomes following its implementation.13 14 22 23
2 Mann C, et al. BMJ Open 2016;6:e011260. doi:10.1136/bmjopen-2016-011260
Open Access
copyright.
 o
n
 January 27, 2020 at University of East Anglia. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-011260 on 4 May 2016. Downloaded from 
Until recently, there has been a lack of guidance for
the design of process evaluations of complex interven-
tions of healthcare trials and protocols are not com-
monly published. However, the recently published
Medical Research Council (MRC) guidance on the
process evaluation of complex interventions provides a
comprehensive set of recommendations.12 Among these
are recommendations that process evaluation research-
ers should prospectively state the aim of the evaluation
and the research objectives, identify the processes they
plan to study, the methods they will use and how they
plan to integrate process and outcome data when analys-
ing the results. This paper aims to fulfil those
recommendations.
PROCESS EVALUATION METHODS
Process evaluation design considerations
Variation in implementation of the 3D intervention is
likely, due to multiple intervention components and
diverse contexts and participants, both clinicians and
patients. Practices’ differing characteristics influence
their care arrangements for patients with LTCs and will
affect the roles and expectations of clinical and adminis-
trative staff as well as patients’ baseline experience and
expectations of care. These differences, together with
diverse local healthcare environments, policies and pri-
orities may affect the ease with which the intervention
integrates with existing practice and the extent of the
change from usual practice. In addition, during the
period of the trial, policy initiatives around health and
social care integration and avoiding emergency hospital
admission are likely to increase and other new incenti-
vised services addressing the needs of those with LTCs
may be introduced. These may differ across areas and
will at least partly target the trial patient population,
potentially affecting both the intervention and usual
care. All of these factors may impact outcomes and con-
stitute the context to be evaluated.
Contextual differences mean that assessment of fidel-
ity must allow for local adaptation. Controlling the form
of the intervention too tightly may undermine, rather
than enhance, its effectiveness11 and local adaptation
may actually result in more successful implementation of
the principles of the intervention. The intervention
description has therefore been framed in terms of strat-
egies and principles, with additional detail where this is
considered essential to implementation (figure 1). This
will form the basis for evaluation—fidelity of function,
rather than fidelity of form.11 Modifications made to the
Figure 1 3D logic model including theoretical mechanisms of action. 3D, dimensions of health, drugs and depression; GP,
general practitioner; LTC, long-term condition; QOL, quality of life.
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intervention to facilitate implementation within the local
context can be assessed as to whether they are consistent
with the definition of the intervention and fulfil fidelity
criteria.24 A thorough record of varying contexts and
corresponding adaptations will facilitate replication in
other settings.24
The design of the main trial process evaluation was
informed by the external pilot and is primarily based on
a recently published framework for process evaluation of
cluster randomised controlled trials.22 The framework,
which describes the various trial stages as potential
targets for evaluation, has been used to guide selection
of the most relevant targets in this case. The interven-
tion diagram (figure 1) serves also as a logic model for
identifying assumed mechanisms of action, as recom-
mended by the recently published MRC guidance on
process evaluation of complex interventions.12 The
mechanisms of action provide the focus of the process
evaluation within the selected stages. Many of these can
be grouped under the concept of patient-centred care
but, in common with many complex interventions, there
is no single intervention theory that explains them all.12
Normalisation process theory (NPT)25 is relevant to the
implementation and maintenance of the intervention
and has helped to inform the process evaluation design,
for example, in considering the effect of practice
context and existing organisation of care on how the
intervention may integrate with usual practice.
To make best use of limited evaluation resources, it is
necessary to focus on factors that may have the greatest
impact on implementation and/or on areas that are
considered critical to the success of the intervention and
which may be vulnerable to poor implementation.12 22
Since the external pilot confirmed that there are signifi-
cant differences in practice size and organisation and
that these drive variation in how the intervention is
adopted, delivered and maintained, context is a key
focus. Variation in adoption, delivery and maintenance
as well as patients’ responses to the intervention, affect-
ing both reach and fidelity, are likely to be important
factors in outcome differences. Therefore, these trial
stages, in addition to context, will form the scope of the
evaluation. The concept of patient-centred care will
inform the evaluation since this is the core concept
underlying the intervention. The dimensions of the
evaluation for the main trial are illustrated in figure 2
and are as follows:
1. Context of each practice, including the practice’s struc-
ture and organisation of care and its local context;
2. Practices’ adoption of the intervention, including
necessary organisational changes;
3. Practice health professionals’ delivery of the interven-
tion to patients;
4. Response of patients to the intervention;
5. Maintenance and unanticipated effects, including
impact of expected incentives and other measures
intended to support implementation and
maintenance.
Recruitment of practices and patients will be evaluated
as part of the main trial. Although research team activity
in training the practices is arguably an important part of
the intervention, this was evaluated and optimised
during the external pilot and it is not included in the
scope of the main trial evaluation.
Aims and objectives
The overall aim of the process evaluation is to better
understand how and why the intervention was effective
or ineffective, and to identify contextually relevant strat-
egies for successful implementation as well as practical
difficulties in adoption, delivery and maintenance to
inform wider implementation.
Objectives are:
1. To establish practice and local health area context in
all intervention and usual care practices at the begin-
ning and end of the trial period to:
A. Identify differences in usual care and how this
might have affected adoption, delivery and
maintenance;
B. Identify changes in the care of patients with multi-
morbidity occurring in intervention and usual
care practices during the trial period which might
affect outcomes.
2. To explore how and why organisational aspects of the
3D intervention were implemented (or not).
3. To explore how health professionals in case study
practices delivered the intervention to patients,
whether all components were included, how and why
it varied, and to what extent they changed their prac-
tice to make it more patient centred.
4. To explore how patients responded to the 3D inter-
vention and to what extent they experienced care as
patient centred.
5. To explore how and why practices maintained (or
did not maintain) reach and delivery of the
intervention.
Figure 2 illustrates the design of the process evalu-
ation, the trial stages that have been prioritised and how
the objectives relate to the stages.
Overall design
The overall design is a mixed-methods study using quan-
titative and some qualitative data from all practices, and
observation, interview and focus group data from four
purposively selected case study practices.
Data from all practices
Mixed quantitative and qualitative data will be collected
from all trial practices, including those in the usual care
arm, using a purpose-designed practice profile form.
Practices will be profiled, including size and organisa-
tional characteristics and how they manage LTC reviews.
This will facilitate assessment of practice context and
effects of contextual variation. In intervention practices
only, collection of quantitative data via the EMIS web
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electronic patient record system will contribute to the
evaluation of fidelity by showing whether or not each
component of the intervention was delivered in each
intervention practice. Some of these data will be used as
part of the intervention to provide monthly feedback to
practices to support maintenance, as well as in the
process evaluation. The data will provide information
about continuity of care and appointments as well as
clinician delivery of 3D review components and the
reach of the intervention.
Case studies
Sampling and recruitment
A minimum of four intervention practices will be pur-
posively sampled as case studies.26 The aim will be to
achieve a sample that encompasses variety in interven-
tion implementation and maintenance, using informa-
tion available shortly after practices are randomised. A
judgement will be made on the basis of information
available from the researchers training the practices
about how the practices plan to implement the interven-
tion and any difficulties they have identified, supplemen-
ted by information about differences in size of practice,
and assessed similarity of usual care at baseline to the
3D intervention. This is based on the assumptions that:
(1) practices that are already organised in a way that is
more consistent with 3D may adopt it more readily and
(2) that larger practices may have lower continuity of
care and a lower proportion of their clinicians taking
part in 3D which may affect implementation, mainten-
ance and outcomes. Data that would allow us to sample
directly for variation in adoption, delivery and mainten-
ance will not be available prospectively. However, we
anticipate that the above criteria will result in sufficient
heterogeneity to provide examples of relatively poor and
relatively good adoption, delivery and maintenance, and
will allow us to identify barriers and facilitators to imple-
mentation and to generate hypotheses about factors that
may be associated with differing outcomes. Adoption
includes the steps described in figure 1 under ‘Practices
Figure 2 Conceptual diagram showing focus of 3D process evaluation. 3D, dimensions of health, drugs and depression; GP,
general practitioner.
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organisation of care’, such as allocating a usual GP, and
delivery includes the components listed in figure 1
under ‘Clinicians conduct of reviews’, for example, pro-
vision of a health plan.
The practices will be sampled and enrolled into the
process evaluation as case studies before or soon after
they have received their training and begun implemen-
tation because not all the information on which sam-
pling is based will be available before then. Data will be
collected from that point and continue throughout the
delivery of the intervention, which will allow us to
observe the whole process of their participation in the
trial from set-up through to completion. Although only
four case study practices will be followed through the
entire process, some flexibility over the number of prac-
tices investigated and the number of interviews con-
ducted will be retained to allow for ‘responsive’
qualitative data collection in additional practices to
investigate emerging issues.12 For example, a practice
that has organisational challenges, such as staff
shortages, or nursing skill mixes that may affect set-up or
fails to adopt as expected, or one that fails to deliver an
element of the intervention (see figure 1), will poten-
tially be sampled later on. This will depend on findings
that emerge from ongoing concurrent analysis. If
resources allow, a usual care practice may also be
recruited as a case study to provide a comparison to care
provided in intervention practices and to check whether
findings from case study practices are reflective of the
intervention, and not simply due to evolving usual care.
Health professionals participating in 3D in the case
study practices will be purposively sampled to achieve
maximum diversity of role and experience, for example,
inclusion of healthcare assistants as well as research
nurses and practice nurses in the nurse sample. The
lead GP, practice manager or other practice staff may be
interviewed depending on implementation or delivery
issues uncovered in the course of data collection.
Patients of case study practices who have received 3D
reviews will be sampled for variation taking into account
age, gender, combination of health conditions and usual
GP/nurse.
When practices and clinicians are approached to par-
ticipate in the main trial, they will be informed that a
process evaluation will be conducted and that participa-
tion in the process evaluation is optional. Additional
written information will be provided to individual staff
invited to participate in interviews and/or observation
and recording of consultations and their informed
consent secured. Patients consenting to participate in
the trial will be informed that they may be invited to
take part in an interview, focus group or observation of
consultations for the process evaluation. If they are
sampled for inclusion, they will receive detailed informa-
tion and their consent will be obtained, prior to their
involvement in the process evaluation.
Case study data collection
The qualitative data collected from the case study prac-
tices will provide more in-depth understanding of the
context of each practice, how the practices implement,
experience and maintain the intervention, and how
their patients experience receiving it, for example,
whether a patient-centred approach was achieved. The
case studies will also shed light on whether, how and
why variation occurs in delivery of each of the interven-
tion components and how context and implementation
interact. A variety of qualitative methods will be used in
Table 1 Methods for objective 1
Objective Sample Data collection
1. To characterise usual care in all GP practices at
the beginning and end of the trial period to identify
variation in usual care and how this might have
affected adoption and to identify changes in the
care of patients with multimorbidity occurring in
intervention and usual care practices during that
time which might affect outcomes
All trial
practices
A. Completion of practice profile form for every practice
at baseline and at the end of the trial to characterise
practice organisation and usual care for LTCs. Data
will include list size, number of nurses and GPs,
management of chronic disease review, and local
healthcare commissioning initiatives to which the
practice has responded. Informal interviews with the
lead administrator and/or lead nurse will be
conducted at the beginning and end of the
intervention period in all practices to clarify practice
organisational systems and whether and how they
change in response to the intervention and to
changing healthcare commissioning requirements
B. Quality and Outcomes Framework27 data from each
practice will capture variation in care provision and
outcomes for the included diseases
C. The COC measure28 will be used to assess to what
extent patients in each practice receive longitudinal
continuity of care
COC, continuity of care; GP, general practitioner; LTC, long-term condition.
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the case studies, including focus groups with patients,
interviews with staff and patients, observation and/or
recording of 3D review consultations and field notes. In
the course of repeated visits to the practice, informal
observation together with field notes will contribute to
understanding the practice context. Interviews with
reception staff and observation of reception functions
will clarify how 3D appointments are being arranged.
To add to case study data into the effect of local
context on implementation, broader contextual data will
be obtained from interviews with healthcare commis-
sioners in each trial site. This will enable assessment of
differences between health areas and co-occurring
changes in the wider healthcare environment and indi-
cate how the intervention might be received in different
healthcare environments.
Qualitative data will be collected using an encrypted
digital audio-recording device. Field notes will be made
at each practice visit. Audio data will be transcribed ver-
batim and anonymised prior to analysis.
Methods for each of the five objectives are described
in tables 1–5.
ANALYSIS
Data about usual care from all practices
Quantitative and qualitative data about usual care in all
trial practices will be used to assess similarity of care at
baseline to the intervention and to assess whether this
changes over the course of the trial. A baseline descrip-
tion of the practice and of its usual care for patients
with multimorbidity will allow comparison of care across
practices and across areas. By repeating this at the end
of the trial, it will also allow us to assess whether usual
care has changed over the course of the trial, and feed
into interpretation of results by facilitating comparison
of care provided by intervention and usual care prac-
tices. If there is a clear trend towards initiatives that are
very similar to 3D, any improvements in care resulting
from 3D may be matched by those that occur as a result
of ‘secular trends’.29 It is also expected that the various
components of the intervention may not be uniformly
implemented across practices, in part due to differences
in context, for example, nurse roles, baseline arrange-
ments for LTC care and whether the practice has their
own pharmacist, and that this may be reflected in differ-
ences in outcomes. Therefore, variation in outcomes by
practice will be compared with variation in practice
characteristics to generate hypotheses about any associa-
tions observed.
Quantitative data from all intervention practices
The quantitative data collected from all intervention
practices will be subject to descriptive statistical analysis
to provide information about the differential implemen-
tation rates of the intervention components. This will be
Table 2 Methods for objective 2
Objective Sample Data collection
2. To explore how and why
organisational aspects of
the 3D intervention were
implemented (or not)
Case study
practices
Quantitative data:Using EMIS compatible software the trial team will collect
information about
A. Number of recruited patients flagged on EMIS and given a 3D card.
B. When each practice begins to deliver 3D reviews
The practice profile form will provide additional information about the
number of participating clinicians and nurses and usual care at baseline.
Qualitative data:
C. The process evaluation researcher will attend the training of some
intervention practices in each area to observe how the training is delivered,
how the practice staff respond and what difficulties they anticipate.
D. Informal interview with the research associate working with each case
study practice to obtain their impression of the practice and ease of study
set-up, for example, whether they have experienced difficulty in arranging
meetings or training sessions with practice staff, whether any difficulties
have been identified and whether there are any staff who particularly
support or oppose the intervention.
E. Semistructured interviews in each case study practice with the lead
administrator responsible for arranging reviews, the lead nurse and the
lead GP to be conducted when the practice has completed training.
Questions will be asked about current care arrangements for patients with
LTCs, their opinion of the training received from the research team, and the
intervention and its requirements. They will also be asked how the practice
has organised appointments to accommodate 3D patients and what
barriers and facilitators they are aware of that may affect implementation.
F. Observation and informal interviews of reception staff to understand how
care is being organised for participating patients and how they actually go
about arranging appointments.
3D, dimensions of health, drugs and depression; GP, general practitioner; LTC, long-term condition.
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related to trial outcomes and will facilitate comparison
of case study practices with all intervention practices
regarding implementation fidelity.
Case study data
The qualitative data will be analysed in parallel with
ongoing data collection, so that exploration of emerging
issues can be incorporated into future data collection
and further sampling of practices or individuals can take
place subject to resource availability. NVivo V.10 software
(QSR International) will be used to facilitate develop-
ment of a coding matrix following framework princi-
ples,30 with built in flexibility to allow identification of
anticipated and emergent themes. A flexible framework
analysis is an appropriate method to use, in addition to
detailed case study descriptions, since we are interested
in specific problems to do with multimorbidity, specific
intervention components and implementation issues
that may run across practices, while also being con-
cerned to capture new unexpected issues that arise
during the course of the process evaluation. The field
notes from training observation and practice visits will
help to generate rich descriptions of the individual case
study sites while the consultation observations will give
detailed insight into the conduct of reviews. Evaluation
of the patient centredness of the interactions will be
based on an analysis of the interactions, informed by a
conversation analytic approach.31 The transcripts of
these will be coded alongside transcripts from the inter-
views and focus groups to provide different perspectives
on the implementation of the intervention and contrib-
ute to fidelity assessment along with the quantitative
Table 3 Methods for objective 3
Objective Sample Data collection
3. To explore how health
professionals in case study
practices delivered the
intervention to patients,
whether all components were
included, how and why it
varied, and to what extent
they changed their practice to
make it more patient-centred
Health professionals
in case study
practices
Quantitative data:
A. Proportion of pharmacy reviews completed
B. Proportion of 3D patients screened for depression
C. Proportion of 3D patients who receive a printed agenda to take
to part 2 of the review
D. Proportion of 3D patients receiving a health plan and provided
with a printed copy
Qualitative data:
E. Non-participant observation and recording of consultations to
assess fidelity of delivery of the 3D intervention to patients.
With consent from both patient and clinician, the researcher will
video-record or observe and/or audio record up to 20
consultations conducted by GPs and by nurses with patients
participating in the trial. Observation will cover the extent to
which all components of the reviews are included, how the
consultation template is used and responses of patients and
health professionals to the reviews. Observation of consultation
style and techniques will inform evaluation of patient
centredness.
F. De-briefing following consultation observation. A sample of 2
nurses and 2 GPs from each case study practice who have
consented to having a consultation observed and/or audio
recorded will if possible be de-briefed afterwards to gain more
insight into their management of the consultation, where
possible using extracts from the consultation to prompt recall.
G. Semistructured interviews with a sample of nurses and GPs to
obtain views of the intervention, and explore experiences of
delivering the intervention to patients. At least 1 nurse and 1
GP and up to 2 others from each case study practice will be
asked to consent to interviews during the course of
intervention delivery to assess whether there are barriers or
facilitators affecting delivery, whether roles and practice are
significantly changed by the intervention, and the response of
the health professionals to the intervention.
H. A selection of electronic patient records will be reviewed at the
end of the trial to assess the content of pharmacist
recommendations and whether they were acted on by the GP,
and to assess how the agenda compiled by the nurse was
reflected in the GP’s subsequent consultation and health plan.
3D, dimensions of health, drugs and depression; GP, general practitioner.
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data from all intervention practices. Detailed under-
standing of the context of the case study sites, for
example, availability of nurses with appropriate skills,
will contribute to understanding how different contexts
may influence intervention implementation and to what
extent findings can be transferred between sites.
Techniques of constant comparison32 will be used to
generate initial codes that will be built into higher level
Table 4 Methods for objective 4
Objective Sample Data collection
4. To explore how patients
responded to the 3D
intervention and to what
extent they experienced
care as patient-centred
Patients of case
study practices
Semistructured interviews/focus groups with patients to assess patients’
views of care and response to the intervention.
A. A sample of patients will be asked to consent to a focus group to
compare their experience of usual care with their experience of 3D care
and to comment on organisation of care and degree of support in
management of their LTC. Focus groups will be used because this is
likely to generate richer data through discussion of diverse experiences.
B. Up to 4 patients from each case study practice will be asked to consent
to interviews after the intervention has been implemented to assess their
response to the intervention and opinion of its impact. Individual
interviews rather than focus groups will be used for this because patients
will be asked about their individual consultations and condition-specific
care. Some of these patients will be those who have consented to
having one of their 3D reviews recorded and/or observed and will be
invited to interview soon after one of their consultations has been
recorded in order to discuss the consultation, using extracts from the
recording to prompt recall and facilitate discussion of the consultation.
Questions to be discussed will depend on preliminary analysis,
considering interaction, such as agreement or disagreement, and
content, such as the patient’s agenda. The questions will aim to
elucidate the observed interaction between patient and clinician.
3D, dimensions of health, drugs and depression; LTC, long-term condition.
Table 5 Methods for objective 5
Objective Sample Data collection
5. To explore how and
why practices
maintained (or did not
maintain) reach and
delivery of the
intervention
Case study
practices
Quantitative data:
A. Number of reviews delivered month by month over the course of the
intervention
B. Proportion of participating patients given a 3D review every 6 months
C. Proportion of 3D patients’ appointments that are with designated nurse or GP
D. Proportion of pharmacy reviews completed
E. Proportion of 3D patients screened for depression
F. Proportion of 3D patients receiving an agenda completed with their problems
to take to part 2 of the review
G. Proportion of 3D patients receiving a health plan and provided with a printed
copy
H. Number of practice champion meetings attended
Qualitative data:
I. Semistructured interview towards the end of the trial period with the 3D lead
GP and lead administrator in each case study practice to explore how the
practice accommodated 3D, what problems were encountered and what
facilitated or hindered maintenance of the intervention
J. Semistructured interview with at least 1 nurse and GP from each case study
practice who have delivered the intervention (same sample as in 3G) to
explore their perceptions of how well the intervention was accommodated
within the practice structures and how it affected their role and practice
K. Informal interview with research associate for each site. This may be
undertaken at more than 1 time point to obtain their views about the
implementation and maintenance of the intervention in each case study
practice and any particular difficulties or facilitating factors they have identified.
3D, dimensions of health, drugs and depression; GP, general practitioner.
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categories and themes, both within and across the case
studies. Themes relating to the key components of the
intervention and how they were implemented, main-
tained and received will help to interpret trial results
and generate hypotheses about factors influencing
effectiveness. In particular, we will examine the data for
insights into whether patient-centred care has been
delivered, experienced and maintained, as this is the
concept underpinning the intervention and a main
focus of the evaluation. Emerging themes and the rela-
tionship of the data to the conceptual literature under-
pinning the intervention and relevant theories, such as
NPT,25 will be discussed and refined at team meetings
throughout the research. Analysis will be strengthened
by the involvement of more than one person in the ana-
lysis, including a member of the patient public involve-
ment group, to check trustworthiness and credibility of
interpretation of the qualitative data. This group will
also provide the patient perspective on indicators of
patient-centred behaviour to inform analysis of interac-
tions in the consultation recordings.
Integration of the qualitative and quantitative case
study data regarding implementation of different com-
ponents of the intervention will allow detailed evaluation
of the quality of intervention implementation in each
case study site. For example, quantitative data relating to
the number and type of patient problems identified for
the agenda and included in the health plan can be inte-
grated with observational data about how clinicians
addressed agenda setting and health planning. The add-
itional integration of interview data about patients’ and
clinicians’ experiences of reviews will provide in-depth
insight into those processes.
Integrating results of analysis
The process evaluation data will be analysed before
knowing the trial results and the main trial will be ana-
lysed independently of the process evaluation findings.
Once both analyses are complete, combined analysis of
qualitative and quantitative data across the cases may
help to develop explanatory hypotheses about why the
intervention appeared to be implemented more success-
fully in one site than another and some components
were implemented whereas others were not. This may
lead us to identify factors which are plausibly and/or
consistently related to successful or unsuccessful delivery
of the components of the intervention and changes to
patients’ experience of care.13 26 Analysis of the differen-
tial implementation of various components may also
help to elucidate causal mechanisms and suggest which
components of the intervention were more effective and
how and why. Following statistical analysis of trial out-
comes, the qualitative data may be re-examined in the
light of the trial results to help explain them. If appro-
priate, the trial statistician may carry out additional ana-
lysis to test hypotheses generated from integration of the
process evaluation data with the trial outcomes.
The final stage of analysis will be to draw together the
findings from the broader quantitative analysis and the
in-depth case studies to create an understanding of why
the intervention did (or did not) work in all or some
contexts, and identify implications for longer term
implementation if appropriate.
ETHICS AND DISSEMINATION
The design of this process evaluation is covered within
the ethics application and overall protocol of the 3D
study (protocol v6.0 05-01-16). A favourable ethical
opinion of the 3D study was given by the Southwest
(Frenchay) NHS Research Ethics Committee: ref 14/
SW/0011 on 20 March 2014.
Findings will be disseminated via peer-reviewed jour-
nals, conferences and seminars with health services com-
missioners and other interested stakeholders. Social
media and newsletters will be used to disseminate head-
line outcomes. Reports will be provided to bodies with
influence in primary care provision such as the Royal
College of General Practitioners and the National
Health Service (NHS) England, as well as to the funding
body and participants.
CONCLUSION
This paper reports the design and methods for the
planned mixed-methods process evaluation of the 3D
trial. The process evaluation protocol and results will con-
tribute to the developing understanding and overall body
of work on the value of process evaluation in complex
health service delivery and clinical trials. The process
evaluation protocol conforms to recommendations
intended to facilitate standardisation of process evalu-
ation design and reporting12 16 22 in order that synthesis
of results of similar trials may become possible in future.
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